Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Linda C. Griffin is active.

Publication


Featured researches published by Linda C. Griffin.


The Annals of Thoracic Surgery | 1994

Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

Abe DeAnda; Steven Coutre; Marc R. Moon; Conrad M. Vial; Linda C. Griffin; Veronica S. Law; Masashi Komeda; Lawrence L. K. Leung; D. Craig Miller

Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamers clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg.kg-1.min-1 dose, the activated clotting time rose with aptamer infusion from 106 +/- 12 seconds to 187 +/- 8 seconds (+/- 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 +/- 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography.(ABSTRACT TRUNCATED AT 250 WORDS)


Nucleosides, Nucleotides & Nucleic Acids | 1995

Structure-Activity Study of Oligodeoxynucleotides Which Inhibit Thrombin

Steven H. Krawczyk; Norbert Bischofberger; Linda C. Griffin; Veronica S. Law; Regan G. Shea; S. Swaminathan

Abstract The 15-mer oligodeoxynucleotide GGTTGGTGTGGTTGG is a potent inhibitor of thrombin and it forms a stable, highly compact structure in solution. Deletions and substitutions by abasic residues, 2′-deoxyinosine, 7-deaza-2′-deoxyguanosine and 8-methyl-2′-deoxyguanosine show that the structural features of the oligodeoxynucleotide are important for its biological activity.


Archive | 1992

Aptamer specific for biomolecules and method of making.

John J. Toole; Linda C. Griffin; Louis C. Bock; John Latham; Daryl Dean Muenchau; Steven H. Krawczyk


Archive | 1995

Aptamers specific for biomolecules and methods of making

Linda C. Griffin; Glenn Albrecht; John Latham; Lawrence L. K. Leung; Eric Vermaas; John J. Toole


Archive | 1994

Method for identifying an oligonucleotide aptamer specific for a target

John J. Toole; John Latham; Louis C. Bock; Linda C. Griffin


Archive | 1994

Aptamer analogs specific for biomolecules

John J. Toole; Linda C. Griffin; Louis C. Bock; John Latham


Antimicrobial Agents and Chemotherapy | 1998

Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs

Kenneth C. Cundy; Cathy Sueoka; Geoffrey Lynch; Linda C. Griffin; William A. Lee; Jeng-Pyng Shaw


Archive | 1992

Aptamers specific for thrombin and methods of use

John J. Toole; Linda C. Griffin; Louis C. Bock; John Latham; Steven H. Krawczyk


Journal of Medicinal Chemistry | 1998

N2- and C8-substituted oligodeoxynucleotides with enhanced thrombin inhibitory activity in vitro and in vivo

Gong-Xin He; Steven H. Krawczyk; S. Swaminathan; Regan G. Shea; Joseph P. Dougherty; Terry Terhorst; Veronica S. Law; Linda C. Griffin; Steven Coutre; Norbert Bischofberger


Journal of Medicinal Chemistry | 1996

New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.

Choung U. Kim; Lawrence R. McGee; Steven H. Krawczyk; Erik Harwood; Yoko Harada; S. Swaminathan; Norbert Bischofberger; Ming S. Chen; Julie M. Cherrington; Shelly F. Xiong; Linda C. Griffin; Kenneth C. Cundy; Angela Lee; Betty Yu; Sergli Gulnik; John W. Erickson

Collaboration


Dive into the Linda C. Griffin's collaboration.

Top Co-Authors

Avatar

John Latham

National Center for Atmospheric Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Betty Yu

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge